SGEN - Seattle Genetics, Inc.
117.16 0.00 (0.00%)
After hours: 4:35PM EST
| Previous Close | 118.35 |
| Open | 118.64 |
| Bid | 100.02 x 900 |
| Ask | 119.70 x 800 |
| Day's Range | 116.68 - 118.82 |
| 52 Week Range | 51.50 - 122.36 |
| Volume | 799,700 |
| Avg. Volume | 1,065,340 |
| Market Cap | 20.08B |
| Beta (3Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.87 |
| Earnings Date | Feb 5, 2020 - Feb 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 113.07 |
- Zacks
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
- Zacks
Seattle Genetics, Astellas Tie Up With Merck for Cancer Study
Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda combo in patients with previously untreated metastatic urothelial cancer.
- Investopedia
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
- American City Business Journals
This is what workers earn at some of Washington's largest public companies
It's only the second year median worker pay disclosures have been required, and not all the more than 70 public companies in Washington state have released those figures.
- Business Wire
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through a subsidiary, to evaluate the combination of Seattle Genetics’ and Astellas’ antibody-drug conjugate (ADC) enfortumab vedotin and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with previously untreated metastatic urothelial cancer.
- Zacks
Seattle Genetics (SGEN) Up 15.7% Since Last Earnings Report: Can It Continue?
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Benzinga
The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
- Business Wire
Seattle Genetics Announces Health Canada Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
- Approval of Supplemental New Drug Submission for ADCETRIS in Combination with CHP Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma based on Positive Phase 3 E
- Investopedia
The Medicines Company Soars Amid Acquisition Whispers
The Medicines Company climbed to an all-time high Tuesday after takeover rumors surfaced. Play the momentum using these tactical ideas.
- Benzinga
The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
- Business Wire
Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership
Seattle Genetics, Inc. (SGEN) today announced that it has submitted an arbitration demand to the American Arbitration Association to resolve its dispute with Daiichi Sankyo Co. Ltd. regarding the ownership of certain technology used by Daiichi Sankyo in its metastatic breast cancer drug candidate (DS-8201, [Fam-] trastuzumab deruxtecan), among other product candidates. Seattle Genetics contends that the linker and other ADC technology used in these drug candidates are improvements to Seattle Genetics’ pioneering ADC technology, the ownership of which was assigned to Seattle Genetics under the terms of a 2008 collaboration agreement between the two companies.
- Business Wire
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting
-Four-Year Update of the ECHELON-1 Trial Continues to Support Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Advanced Ho
- Business Wire
Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate
Seattle Genetics, Inc. (SGEN) and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160) today announced that the companies have entered into a license agreement for an advanced preclinical product candidate for treating cancer. The agent utilizes a proprietary Seattle Genetics antibody-based technology and is expected to advance into clinical trials in the first half of 2020. Under the terms of the agreement, Seattle Genetics has retained rights to the product candidate in the Americas (United States, Canada and Latin American countries), Europe and Japan.
- Benzinga
The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
- Business Wire
Seattle Genetics Responds to Daiichi Sankyo’s Complaint for Declaratory Judgment
ADC technology used in Daiichi Sankyo’s metastatic breast cancer drug candidate (DS-8201, [Fam-] trastuzumab deruxtecan) among other product candidates, rightfully belongs to Seattle Genetics under the agreement entered into between the two parties in 2008. The linker and other ADC technology used in these drug candidates are improvements to Seattle Genetics’ pioneering ADC technology, the ownership of which are automatically assigned to Seattle Genetics under the terms of the agreement.
- Business Wire
Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference
Seattle Genetics, Inc. announced today that management will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 10:20 a.m. Mountain Time.
- Thomson Reuters StreetEvents
Edited Transcript of SGEN earnings conference call or presentation 29-Oct-19 8:30pm GMT
Q3 2019 Seattle Genetics Inc Earnings Call
- Zacks
Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark
Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.
- Zacks
Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -45.95% and 1.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Seattle Genetics Reports Third Quarter 2019 Financial Results
-Record ADCETRIS® Net Sales in U.S. and Canada of $167.6 Million in the Third Quarter, an Increase of 32 Percent Over the Third Quarter of 2018-
- Benzinga
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Earnings, clinical trial readouts and positive FDA verdicts catalyzed fairly robust performances by biotech stocks last week. Biogen Inc (NASDAQ: BIIB )'s about-face with respect to its Alzheimer's drug ...
- Zacks
Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates
Key highlights of the past week include acquisition news, and regulatory and pipeline updates.
- TheStreet.com
Seattle Genetics: Where's This Biotech Stock Headed From Here?
During Monday night's Lightning Round of Mad Money one caller asked about Ionis Pharmaceuticals Inc. : "This is a battleground. In the daily bar chart of SGEN, below, we can see that the prices have just about doubled in the past 12 months. The On-Balance-Volume (OBV) line has turned upward in the past two months to support and confirm the price advance and tell us that buyers of SGEN have been more aggressive.
